EDITAS MEDICINE, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
EDITAS MEDICINE, INC. (EDIT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 68.27 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.12M shares, a 2.87% increase year-over-year.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 12.75M shares, a 21.22% increase year-over-year.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 10.52M shares, a 29.11% increase year-over-year.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 8.11M shares, a 20.63% increase year-over-year.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 9.00M shares, a 9.85% decline from fiscal 2024.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 9.98M shares, a 20.90% increase from fiscal 2023.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.26M shares, a 21.87% increase from fiscal 2022.
- EDITAS MEDICINE, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.78M shares, a 85.89% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 68.27M shares 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | 13.12M shares 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | 9.00M shares 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 9.63M shares 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 11.37M shares 10-Q · filed 2026-08-05 | ||||
| 2025-03-31 | 12.75M shares 10-Q · filed 2026-05-05 | ||||
| 2024-12-31 | 9.98M shares 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 10.71M shares 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 10.89M shares 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | 10.52M shares 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | 8.26M shares 10-K · filed 2025-03-05 | ||||
| 2023-09-30 | 8.11M shares 10-Q · filed 2023-11-03 | 8.11M shares 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | 8.27M shares 10-Q · filed 2023-08-02 | 8.27M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 8.15M shares 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | 6.78M shares 10-K · filed 2024-02-28 | ||||
| 2022-09-30 | 6.72M shares 10-Q · filed 2023-11-03 | 6.72M shares 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | 6.48M shares 10-Q · filed 2023-08-02 | 6.48M shares 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | 5.15M shares 10-Q · filed 2023-05-05 | ||||
| 2021-12-31 | 3.64M shares 10-K · filed 2023-02-22 | ||||
| 2021-09-30 | 3.83M shares 10-Q · filed 2022-11-02 | 3.83M shares 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | 4.11M shares 10-Q · filed 2022-08-03 | 4.11M shares 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | 4.63M shares 10-Q · filed 2022-05-04 | ||||
| 2020-12-31 | 4.81M shares 10-K · filed 2022-02-24 | ||||
| 2020-09-30 | 4.00M shares 10-Q · filed 2021-11-09 | 4.55M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 4.50M shares 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | 5.50M shares 10-Q · filed 2021-05-06 | 5.11M shares 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | 4.94M shares 10-K · filed 2021-02-26 | ||||
| 2019-09-30 | 5.73M shares 10-Q · filed 2020-11-06 | 5.73M shares 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | 5.04M shares 10-Q · filed 2020-08-07 | ||||
| 2019-03-31 | 5.50M shares 10-Q · filed 2020-05-08 | ||||
| 2018-12-31 | 4.96M shares 10-K · filed 2020-02-26 | ||||
| 2018-09-30 | 5.11M shares 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | 5.41M shares 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | 5.71M shares 10-Q · filed 2019-05-08 | ||||
| 2017-12-31 | 5.13M shares 10-K · filed 2019-03-01 | ||||
| 2017-09-30 | 4.68M shares 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | 5.79M shares 10-Q · filed 2018-08-07 | ||||
| 2017-03-31 | 5.60M shares 10-Q · filed 2018-05-04 | ||||
| 2016-12-31 | 4.23M shares 10-K · filed 2018-03-08 | ||||
| 2016-09-30 | 4.11M shares 10-Q · filed 2017-11-08 | ||||
| 2016-06-30 | 3.81M shares 10-Q · filed 2017-08-09 | ||||
| 2016-03-31 | 3.80M shares 10-Q · filed 2017-05-15 | ||||
| 2015-12-31 | 28.26M shares 10-K · filed 2017-03-03 | ||||
| 2015-09-30 | 27.96M shares 10-Q · filed 2016-11-09 | ||||
| 2015-06-30 | 10.56M shares 10-Q · filed 2016-08-10 | ||||
| 2015-03-31 | 10.79M shares 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |